BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes
BeOne reports new liver and lung cancer responses across three Phase 1 drugs, but dosing, safety and confirmatory evidence will shape development.
Pharma & Biotech
Pharma & Biotech
Ziihera extends overall survival versus trastuzumab in Phase 3 first-line HER2-positive gastroesophageal cancer trial
Jazz Pharmaceuticals says a second interim analysis of HERIZON-GEA-01 found statistically significant and clinically meaningful overall survival improvement with Ziihera plus chemotherapy versus trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma.
Pharma & Biotech
Ziihera moves into first-line HER2-positive cancer treatment after pivotal Phase 3 results
FDA expands Ziihera into first-line HER2-positive gastroesophageal cancer. See how the approval could reshape treatment and Zymeworks growth.
Pharma & Biotech
Can CX-5461 make resistant tumors respond to immunotherapy? Senhwa’s Taiwan clearance opens the clinical test
Senhwa Biosciences has secured Taiwan regulatory clearance for a multicenter Phase 1b/2a trial combining pidnarulex, or CX-5461, with BeOne Medicines’ PD-1 inhibitor tislelizumab in advanced solid tumors. The study will test whether DNA replication stress can make immunologically cold or checkpoint-resistant cancers more responsive to immunotherapy.
Pharma & Biotech
Senhwa’s NT$500m GEM deal sounds like fresh funding, but the structure is more complicated
Senhwa formalises a NT$500 million GEM share purchase pact, but direct funding, dilution and pipeline execution remain the decisive questions.
Pharma & Biotech
Can Senhwa’s CX-5461 finally turn cold tumors hot in immunotherapy’s toughest challenge?
Senhwa Biosciences Inc. and BeOne Medicines have signed a clinical supply agreement to explore a novel drug combination aimed at treating hard-to-reach cancers. The collaboration will test Senhwa’s lead compound Pidnarulex (CX-5461), a G-quadruplex stabilizer, in combination with BeOne’s PD-1 inhibitor tislelizumab. The Phase 1b/2a clinical trial will enroll patients with advanced solid tumors, including